206 related articles for article (PubMed ID: 20661408)
1. p16INK4a expression in basal-like breast carcinoma.
Bohn OL; Fuertes-Camilo M; Navarro L; Saldivar J; Sanchez-Sosa S
Int J Clin Exp Pathol; 2010 Jun; 3(6):600-7. PubMed ID: 20661408
[TBL] [Abstract][Full Text] [Related]
2. p16 promoter methylation, expression, and its association with estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 subtype of breast carcinoma.
Goyal A; Sahu RK; Kumar M; Sharma S; Qayyum S; Kaur N; Singh UR; Mehrotra R; Hedau S
J Cancer Res Ther; 2019; 15(5):1147-1154. PubMed ID: 31603125
[TBL] [Abstract][Full Text] [Related]
3. [Methylation and expression of gene p16INK4a and RB in breast carcinoma].
Zhao YF; Shen SP; Jiang JY; Geng H; Guo JG; Xie LP
Zhonghua Bing Li Xue Za Zhi; 2010 Jun; 39(6):377-81. PubMed ID: 21055153
[TBL] [Abstract][Full Text] [Related]
4. Increased expression of senescence markers p14(ARF) and p16(INK4a) in breast cancer is associated with an increased risk of disease recurrence and poor survival outcome.
Pare R; Shin JS; Lee CS
Histopathology; 2016 Sep; 69(3):479-91. PubMed ID: 26843058
[TBL] [Abstract][Full Text] [Related]
5. p16 expression correlates with basal-like triple-negative breast carcinoma.
Abou-Bakr AA; Eldweny HI
Ecancermedicalscience; 2013; 7():317. PubMed ID: 23717338
[TBL] [Abstract][Full Text] [Related]
6. Basal-like breast carcinomas: clinical outcome and response to chemotherapy.
Banerjee S; Reis-Filho JS; Ashley S; Steele D; Ashworth A; Lakhani SR; Smith IE
J Clin Pathol; 2006 Jul; 59(7):729-35. PubMed ID: 16556664
[TBL] [Abstract][Full Text] [Related]
7. Basal cytokeratin and epidermal growth factor receptor expression are not predictive of BRCA1 mutation status in women with triple-negative breast cancers.
Collins LC; Martyniak A; Kandel MJ; Stadler ZK; Masciari S; Miron A; Richardson AL; Schnitt SJ; Garber JE
Am J Surg Pathol; 2009 Jul; 33(7):1093-7. PubMed ID: 19390427
[TBL] [Abstract][Full Text] [Related]
8. Exploring novel targets of basal-like breast carcinoma by comparative gene profiling and mechanism analysis.
Wu YM; Hu W; Wang Y; Wang N; Gao L; Chen ZZ; Zheng WQ
Breast Cancer Res Treat; 2013 Aug; 141(1):23-32. PubMed ID: 23933801
[TBL] [Abstract][Full Text] [Related]
9. Most basal-like breast carcinomas demonstrate the same Rb-/p16+ immunophenotype as the HPV-related poorly differentiated squamous cell carcinomas which they resemble morphologically.
Subhawong AP; Subhawong T; Nassar H; Kouprina N; Begum S; Vang R; Westra WH; Argani P
Am J Surg Pathol; 2009 Feb; 33(2):163-75. PubMed ID: 18936692
[TBL] [Abstract][Full Text] [Related]
10. Androgen receptor expression in breast cancer in relation to molecular phenotype: results from the Nurses' Health Study.
Collins LC; Cole KS; Marotti JD; Hu R; Schnitt SJ; Tamimi RM
Mod Pathol; 2011 Jul; 24(7):924-31. PubMed ID: 21552212
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical identification of basal-type cytokeratins in invasive ductal breast carcinoma--relation with grade, stage, estrogen receptor and HER2.
Kusińska R; Potemski P; Jesionek-Kupnicka D; Kordek R
Pol J Pathol; 2005; 56(3):107-10. PubMed ID: 16334976
[TBL] [Abstract][Full Text] [Related]
12. FOXC1 identifies basal-like breast cancer in a hereditary breast cancer cohort.
Johnson J; Choi M; Dadmanesh F; Han B; Qu Y; Yu-Rice Y; Zhang X; Bagaria S; Taylor C; Giuliano AE; Amersi F; Cui X
Oncotarget; 2016 Nov; 7(46):75729-75738. PubMed ID: 27708239
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma.
Nielsen TO; Hsu FD; Jensen K; Cheang M; Karaca G; Hu Z; Hernandez-Boussard T; Livasy C; Cowan D; Dressler L; Akslen LA; Ragaz J; Gown AM; Gilks CB; van de Rijn M; Perou CM
Clin Cancer Res; 2004 Aug; 10(16):5367-74. PubMed ID: 15328174
[TBL] [Abstract][Full Text] [Related]
14. High Ki-67 Expression and Low Progesterone Receptor Expression Could Independently Lead to a Worse Prognosis for Postmenopausal Patients With Estrogen Receptor-Positive and HER2-Negative Breast Cancer.
Nishimukai A; Yagi T; Yanai A; Miyagawa Y; Enomoto Y; Murase K; Imamura M; Takatsuka Y; Sakita I; Hatada T; Miyoshi Y
Clin Breast Cancer; 2015 Jun; 15(3):204-11. PubMed ID: 25600243
[TBL] [Abstract][Full Text] [Related]
15. Morphological characteristics of basal-like subtype of breast carcinoma with special reference to cytopathological features.
Ishihara A; Tsuda H; Kitagawa K; Yoneda M; Shiraishi T
Breast Cancer; 2009; 16(3):179-85. PubMed ID: 19466513
[TBL] [Abstract][Full Text] [Related]
16. Triple-negative breast cancer: disease entity or title of convenience?
Carey L; Winer E; Viale G; Cameron D; Gianni L
Nat Rev Clin Oncol; 2010 Dec; 7(12):683-92. PubMed ID: 20877296
[TBL] [Abstract][Full Text] [Related]
17. Androgen receptor in breast cancer: expression in estrogen receptor-positive tumors and in estrogen receptor-negative tumors with apocrine differentiation.
Niemeier LA; Dabbs DJ; Beriwal S; Striebel JM; Bhargava R
Mod Pathol; 2010 Feb; 23(2):205-12. PubMed ID: 19898421
[TBL] [Abstract][Full Text] [Related]
18. Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes.
Kim MJ; Ro JY; Ahn SH; Kim HH; Kim SB; Gong G
Hum Pathol; 2006 Sep; 37(9):1217-26. PubMed ID: 16938528
[TBL] [Abstract][Full Text] [Related]
19. c-Kit expression as a prognostic molecular marker in patients with basal-like breast cancer.
Kashiwagi S; Yashiro M; Takashima T; Aomatsu N; Kawajiri H; Ogawa Y; Onoda N; Ishikawa T; Wakasa K; Hirakawa K
Br J Surg; 2013 Mar; 100(4):490-6. PubMed ID: 23319435
[TBL] [Abstract][Full Text] [Related]
20. Overexpression of the p16 cell cycle inhibitor in breast cancer is associated with a more malignant phenotype.
Milde-Langosch K; Bamberger AM; Rieck G; Kelp B; Löning T
Breast Cancer Res Treat; 2001 May; 67(1):61-70. PubMed ID: 11518467
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
